84 related articles for article (PubMed ID: 17292399)
1. An envelope-determined endocytic route of viral entry allows HIV-1 to escape from secreted phospholipase A2 entry blockade.
Maurin T; Fenard D; Lambeau G; Doglio A
J Mol Biol; 2007 Mar; 367(3):702-14. PubMed ID: 17292399
[TBL] [Abstract][Full Text] [Related]
2. Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.
Fenard D; Lambeau G; Valentin E; Lefebvre JC; Lazdunski M; Doglio A
J Clin Invest; 1999 Sep; 104(5):611-8. PubMed ID: 10487775
[TBL] [Abstract][Full Text] [Related]
3. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
Saunders CJ; McCaffrey RA; Zharkikh I; Kraft Z; Malenbaum SE; Burke B; Cheng-Mayer C; Stamatatos L
J Virol; 2005 Jul; 79(14):9069-80. PubMed ID: 15994801
[TBL] [Abstract][Full Text] [Related]
4. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction.
Marchant D; Neil SJ; Aubin K; Schmitz C; McKnight A
J Virol; 2005 Aug; 79(15):9410-8. PubMed ID: 16014904
[TBL] [Abstract][Full Text] [Related]
5. Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
Baldwin CE; Berkhout B
Retrovirology; 2006 Nov; 3():84. PubMed ID: 17134507
[TBL] [Abstract][Full Text] [Related]
6. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.
Schaeffer E; Soros VB; Greene WC
J Virol; 2004 Feb; 78(3):1375-83. PubMed ID: 14722292
[TBL] [Abstract][Full Text] [Related]
7. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.
Yonezawa A; Cavrois M; Greene WC
J Virol; 2005 Jan; 79(2):918-26. PubMed ID: 15613320
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.
Chazal N; Singer G; Aiken C; Hammarskjöld ML; Rekosh D
J Virol; 2001 Apr; 75(8):4014-8. PubMed ID: 11264394
[TBL] [Abstract][Full Text] [Related]
9. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.
Walter BL; Wehrly K; Swanstrom R; Platt E; Kabat D; Chesebro B
J Virol; 2005 Apr; 79(8):4828-37. PubMed ID: 15795268
[TBL] [Abstract][Full Text] [Related]
10. Endocytic entry of HIV-1.
Fackler OT; Peterlin BM
Curr Biol; 2000 Aug; 10(16):1005-8. PubMed ID: 10985390
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.
Fredericksen BL; Wei BL; Yao J; Luo T; Garcia JV
J Virol; 2002 Nov; 76(22):11440-6. PubMed ID: 12388705
[TBL] [Abstract][Full Text] [Related]
12. Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis.
Stevenson M; Haggerty S; Lamonica C; Mann AM; Meier C; Wasiak A
J Virol; 1990 Aug; 64(8):3792-803. PubMed ID: 1695254
[TBL] [Abstract][Full Text] [Related]
13. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication.
Stamatatos L; Wiskerchen M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 1998 Sep; 14(13):1129-39. PubMed ID: 9737584
[TBL] [Abstract][Full Text] [Related]
14. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry.
Daecke J; Fackler OT; Dittmar MT; Kräusslich HG
J Virol; 2005 Feb; 79(3):1581-94. PubMed ID: 15650184
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
16. Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis.
Andeweg AC; Boers PH; Osterhaus AD; Bosch ML
J Gen Virol; 1995 Aug; 76 ( Pt 8)():1901-7. PubMed ID: 7636471
[TBL] [Abstract][Full Text] [Related]
17. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1.
Milne RS; Nicola AV; Whitbeck JC; Eisenberg RJ; Cohen GH
J Virol; 2005 Jun; 79(11):6655-63. PubMed ID: 15890903
[TBL] [Abstract][Full Text] [Related]
19. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.
Yang X; Kurteva S; Ren X; Lee S; Sodroski J
J Virol; 2005 Oct; 79(19):12132-47. PubMed ID: 16160141
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
Pastore C; Nedellec R; Ramos A; Pontow S; Ratner L; Mosier DE
J Virol; 2006 Jan; 80(2):750-8. PubMed ID: 16378977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
